Common questions about Microvlar (FAQ)
Q: Does Microvlar cause weight gain in most users?
A: Official product information on Microvlar and similar combined oral contraceptives often lists weight changes (either an increase or a decrease) among the potential adverse reactions. These effects are typically reported in the initial cycles of use, but individual responses can vary. Regulatory data reports the possibility of weight change, not that it happens to every user.
Q: Is it normal to have spotting or breakthrough bleeding in the first month of Microvlar?
A: Yes, irregular bleeding, such as spotting or breakthrough bleeding, is commonly reported when women first start Microvlar. According to regulatory data, this is often an expected effect as the body adjusts to the new hormone levels. If this bleeding persists beyond the first few cycles or restarts later in therapy, it may warrant evaluation by a healthcare professional.
Q: How long does it take for side effects from Microvlar to usually go away?
A: Many of the common side effects, such as nausea, breast tenderness, or headaches, are generally expected to be temporary. Official information suggests that these issues typically subside within the first few cycles (often two to three months) as the body adjusts to the hormonal components.
Q: Can Microvlar affect my mood or cause emotional changes?
A: Regulatory documents commonly list mood changes, including depressed mood and nervousness, as potential adverse reactions associated with hormonal contraceptive use. If a user experiences significant or persistent changes in their emotional state while taking Microvlar, a consultation with a healthcare professional may be appropriate.
Q: What should I do if I miss one Microvlar pill?
A: Specific steps for managing a missed dose are outlined in the official patient instructions and depend on how many pills were missed and the week of the cycle. Generally, if a user realizes a dose was missed, the primary guidance is to consult the information provided with the product or contact a healthcare provider for instruction on how to proceed, which may involve using back-up contraception.
Q: Can Microvlar be used by women approaching menopause?
A: Microvlar is not indicated for use in women who are postmenopausal. For women who are approaching menopause (perimenopausal), the decision to use any combined oral contraceptive requires a careful assessment of individual health risks and benefits by a healthcare provider, especially concerning potential cardiovascular risks.
Q: Does Microvlar change the flow or duration of my period?
A: Official information confirms that Microvlar can cause menstrual irregularities, which include changes to the bleeding pattern. This means users may notice a difference in the volume (flow) or the duration of their withdrawal bleeding, or they may experience amenorrhea (a lack of bleeding).
Q: Are there long-term health risks associated with using Microvlar for many years?
A: Regulatory documents state that all combined oral contraceptives carry serious, long-term risks. These include an increased risk of venous thromboembolism (blood clots), arterial thromboembolism (stroke or heart attack), and certain forms of cancer in susceptible individuals. Due to these risks, ongoing health monitoring is an important part of using this medication.
Q: How long until fertility returns after stopping Microvlar?
A: Official pharmacological information indicates that the hormonal suppression of ovulation reverses once the medicine is stopped and cleared from the body. The return of fertility is expected once the hormonal suppression is lifted. Individual timelines for the return of a typical menstrual cycle can vary.
Q: Why do some women experience nausea when they first start Microvlar?
A: Nausea is a common, listed adverse effect of combined oral contraceptives like Microvlar. Official pharmacological explanations attribute this effect to the hormonal content, particularly the estrogen component, as the body adjusts to the systemic hormone levels.
Q: Is my cycle protected during the 'placebo' or inactive week of Microvlar?
A: Protection is generally maintained during the 7 days of inactive tablets, provided that the preceding 21 active tablets were taken correctly and consistently, and that the next pack is started on schedule. Interruptions in the active pill schedule may compromise this protection.
Q: What if I vomit shortly after taking a Microvlar pill?
A: The official instructions outline specific steps for managing potential non-absorption due to severe vomiting or diarrhea that occurs shortly after taking an active pill. Users should consult the product information, as the recommended steps often involve immediate action to ensure contraceptive efficacy, which may require using a back-up method of contraception.
Q: Is Microvlar different from other 'mini-pills'?
A: Yes, Microvlar is a Combined Oral Contraceptive (COC) because it contains two types of hormones: an estrogen and a progestogen. A 'mini-pill' is specifically a Progestogen-Only Pill (POP) and is formulated without the estrogen component.
Q: What is the risk of accidental pregnancy if a dose of Microvlar is taken late?
A: Regulatory instructions define lateness based on a specific time limit, often 12 hours. If an active pill is taken less than 12 hours late, its contraceptive protection is usually maintained. If it is taken more than 12 hours late, it is classified as a missed dose, and the reliability in preventing pregnancy may be reduced.
Q: Can Microvlar be taken by women with a history of migraines?
A: Microvlar is absolutely contraindicated (must not be used) in women who experience migraine headaches with focal neurological symptoms (migraine with aura), due to a significantly increased risk of stroke. Use in women with migraines without aura requires a careful individual risk assessment by a healthcare provider.
Q: Is Microvlar associated with changes in vision or contact lens comfort?
A: Regulatory data lists the possibility of adverse effects on the eyes, which can include intolerance to contact lenses or visual disturbances. If vision changes occur or if wearing contact lenses becomes uncomfortable, these effects may warrant a consultation with a healthcare professional.
Q: Is it true that Microvlar can sometimes cause changes in hair growth or loss?
A: Yes, official regulatory documents list potential adverse effects related to hair, which can include both alopecia (hair loss) or hirsutism (excessive hair growth). These are hormonal effects that can occur, though they are not experienced by all users.
Q: Are there any specific lifestyle factors that can reduce Microvlar's effectiveness?
A: While effectiveness relies primarily on correct usage, the most critical lifestyle factor cited in regulatory documents is smoking. Smoking, particularly in women aged 35 years or older, significantly increases the risk of serious side effects like blood clots, which is why it is listed as an absolute contraindication in this patient group.
